Lantern Pharma (LTRN) Action Cours

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 22 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging its RADR artificial intelligence (AI) and machine learning (ML) platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically targeted therapeutics. Its RADR AI includes more than 25 billion data points and uses big data analytics and ML to uncover biologically relevant genomic signatures correlated to drug response. Its portfolio consists of four compounds, which includes LP-100, LP-300, LP-184, and LP-284, and an Antibody Drug Conjugate (ADC) program: two drug candidates in clinical phases, two in the pre-IND preclinical stage and its ADC program in research optimization. All these drug candidates and its ADC program are leveraging precision oncology, AI, and genomic driven approaches. The company has two drug candidates in clinical development, which are LP-100 and LP-300. The company also has two new drug candidates, LP-184 and LP-284.